Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The neurons of the brain are protected by an insulating layer called myelin. In certain diseases like multiple sclerosis, ...

“If not treated early upon diagnosis, multiple sclerosis can lead to significant, irreversible brain volume loss and cognitive decline,” said Jeffrey Cohen, MD, Mellen Center for Multiple Sclerosis, ...

The following is a summary of “Cerebrovascular hemodynamics association with brain structure and function in Multiple ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Researchers have previously taken images of pregnant women's brains, but these can miss temporary changes in the brain that ...

Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.

C1QL1 promotes the replacement of the cells that produce myelin. Boosting it may improve treatment of demyelinating diseases.